Results

Total Results: 1,939 records

Showing results for "event".

321. Data Development for Patient Safety — A Pilot Study using Medicare Part B Drug Data | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/patient-safety-drug-data/abstract
     January 01, 2005 - Data Development for Patient Safety — A Pilot Study using Medicare Part B Drug Data Abstract January 1, 2005 Topic Abstract Medicare administrative claims data offer a valuable informational source for the surveillance of adverse drug events, but there are substantial challenges in exploiting these d…

322. Standardized Library of Asthma Outcome Measures (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/white-paper-library-asthma.pdf
     April 01, 2019 - Standardized Library of Asthma Outcome Measures Research White Paper Standardized Library of Asthma Outcome Measures Research White Paper Standardized Library of Asthma Outcome Measures Prepared for: Agency for Healthcare Research and Quality Center for Outcomes and Ev…

323. Standardized Library of Asthma Outcome Measures (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/white-paper-library-asthma.pdf
     April 01, 2019 - Standardized Library of Asthma Outcome Measures Research White Paper Standardized Library of Asthma Outcome Measures Research White Paper Standardized Library of Asthma Outcome Measures Prepared for: Agency for Healthcare Research and Quality Center for Outcomes and Ev…

324. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0407_01-20-2011.pdf
     January 01, 2011 - Effective Health Care Topic Number: 0343 Document Completion Date: 3-23-11 1 Results of Topic Selection Process & Next Steps  Peripheral artery disease (PAD) will go forward for refinement as a systematic review. The scope of this topic, including populations, interventions, comparators, and out…

325. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_disposition-comments.pdf
     September 01, 2011 - We have added the following sentence as a Key Point: “Adverse event rates may be underestimated by … In adverse event analysis, page 45, why weren't open label run-in phase data in the withdrawal studies … In the adverse event analysis, we only included data from the RCT phases of multiphase studies in order … Some examples of imbalances in adverse event rates that favor the safety of placebo over adalimumab … We have added the following sentence as a Key Point for KQ3: “Adverse event rates may be underestimated

326. PHARMACO-EPIDEMIOLOGIC METHODS FOR A STUDY OF (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/antipsychotic-medicine-cardiovascular-elderly_research.pdf
     February 01, 2009 - myocardial infarction 60 (0.66) 96 (0.70) 99 (1.08) 151 (1.10) 164 (1.79) 249 (1.81) Cerebrovascular event … Acute myocardial Infarction 0.93 (0.66, 1.32) 1.00 (0.76, 1.30) 1.03 (0.85, 1.27) Cerebrovascular event … Acute myocardial infarction 0.89 (0.59, 1.33) 1.02 (0.75, 1.40) 1.16 (0.91, 1.48) Cerebrovascular event

327. Effects of Dietary Sodium and Potassium Intake on Chronic Disease Outcomes and Related Risk Factors | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/sodium-potassium/research-protocol
     March 01, 2017 - mortality Stroke, coronary heart disease, myocardial infarction Number of patients with any CVD event … a study reports more than one outcome in this category, we will abstract data for only one type of event … mortality Stroke Coronary heart disease Myocardial infarction Number of patients with any CVD event … mortality Stroke Coronary heart disease Myocardial infarction Number of patients with any CVD event … : e.g., mean/median 24-h urinary excretion, status Outcomes: type and definition (e.g., any CVD event

328. Bariatric Surgery and Nonsurgical Therapy in Adults With Metabolic Conditions and a Body Mass Index of 30.0 to 34.9 kg/m² | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/weight-loss-surgery/research
     June 05, 2013 - Current Page Topic Timeline Mar. 10, 2008 Topic Suggestion Dec. 14, 2010 Research Protocol Jun. 5, 2013 Systematic Review Sep. 12, 2013 Disposition of Comments Report Bariatric Surgery and Nonsurgical Therapy in Adults With Metabolic Conditions and a Body Mass Index of 30.0 to 34.9 kg/m² Systematic Review Archived…

329. Antiplatelet and Anticoagulant Treatments for Unstable Angina/Non–ST Elevation Myocardial Infarction | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/angina-heart-attack-treatments/research
     November 04, 2013 - Current Page Topic Timeline Oct. 25, 2011 Topic Initiated Dec. 13, 2012 Research Protocol Nov. 4, 2013 Systematic Review Feb. 13, 2014 Disposition of Comments Report Antiplatelet and Anticoagulant Treatments for Unstable Angina/Non–ST Elevation Myocardial Infarction Systematic Review Archived November 4, 2013 Web …

330. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/rheumatoid-arthritis-medicine-update/final-report-update-2018
     July 16, 2018 - Current Page Topic Timeline Mar. 29, 2017 Topic Initiated May. 24, 2017 Research Protocol Jul. 16, 2018 Systematic Review Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update Systematic Review July 16, 2018 Download Main Document PDF 23.9 MB Related Files Download Disposition of Com…

331. Systematic Review on Treatments for Acute Pain: Surveillance Report 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/main-apps-surv-rept-1-acute-pain.pdf
     February 01, 2022 - NSAID Opioid increased risk of: Any adverse event: RR 1.72 (95% CI 1.29 to 2.28) Nausea: RR 2.72 … acetaminophen Opioids increased risk of: Any adverse event: RR 1.43 (95% CI 0.87 to 2.37) Nausea … Opioids were associated with increased likelihood of any adverse event (34% vs. 9%, RR 3.62, 95% CI … Topical ibuprofen was associated with decreased likelihood of any adverse event, although the estimate … Opioids were associated with increased likelihood of any adverse event (11 trials, pooled RR 1.72, 95%

332. Refining Key Questions: Interactive Case Study Quiz
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/rfviia.pptx
     May 01, 2010 - pageaction=displayproduct&productID=450 Mean Differences in Mortality and Thromboembolic Event Rates … Mean Differences in Mortality and Thromboembolic Event Rates by Study and rFVIIa Indication This figure … The mean differences in event rates for the direct (patient-centered) outcomes of total mortality and … The figures show mean differences in mortality and thromboembolic event rates, respectively, for each … harms of rFVIIa, our findings include: There was no effect of rFVIIa on mortality or thromboembolic event

333. Refining Key Questions: Interactive Case Study Quiz
     effectivehealthcare.ahrq.gov/sites/default/files/rfviia.pptx
     May 01, 2010 - pageaction=displayproduct&productID=450 Mean Differences in Mortality and Thromboembolic Event Rates … Mean Differences in Mortality and Thromboembolic Event Rates by Study and rFVIIa Indication This figure … The mean differences in event rates for the direct (patient-centered) outcomes of total mortality and … The figures show mean differences in mortality and thromboembolic event rates, respectively, for each … harms of rFVIIa, our findings include: There was no effect of rFVIIa on mortality or thromboembolic event

334. Key Questions - Optimal Medical Treatments for Non-Metastatic Gastric Cancers (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/gastric-cancer-key-questions.pdf
     January 01, 2020 - Key Questions - Optimal Medical Treatments for Non-Metastatic Gastric Cancers Optimal Medical Treatments for Non-Metastatic Gastric Cancers Background Gastric cancer is the fifth most common cancer worldwide, and most frequent cause of cancer death in some countries (Sung et al., 2021). In the US, the rate of n…

335. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/treatment-resistant-depression_executive.pdf
     September 01, 2011 - depression (TRD) with strength of evidence for Tier 1 (TRD) for KQ 4c, withdrawals due to adverse event … Adverse event reporting is quite limited and tends to cover only a short time span; what reporting does

336. A Randomized Trial of Epidural Glucocorticoid Injections for Spinal Stenosis: A Brief Summary of Findings for Clinicians | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/glucocorticoid-injections/clinician
     June 29, 2016 - A Randomized Trial of Epidural Glucocorticoid Injections for Spinal Stenosis: A Brief Summary of Findings for Clinicians Clinician Summary June 29, 2016 Download Main Document PDF 134.6 KB Description of This Summary This is a summary of an original research article published in The New England Jour…

337. Management and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/binge-eating_clinician.pdf
     May 01, 2016 - Management and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence Management and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence Focus of This Summary This is a summary of a systematic review evaluating the evidence regarding the effectiveness, comparative effectiv…

338. Treatments for Schizophrenia in Adults: A Systematic (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/executive-summary-2017-schizophrenia-adult.pdf
     January 01, 2017 - Although clozapine is often reserved for treatment-resistant patients, due to the serious adverse event … Given the variation in specific adverse event profiles across the SGAs, withdrawals due to adverse events … All-cause mortality is a rare event, but it is still an important outcome to evaluate as SGAs continue … SGA comparisons Overall Adverse Events • Overall adverse event rates favored SGAs when comparing haloperidol … with aripiprazole • Overall adverse event rates favored SGAs when comparing haloperidol with risperidone

339. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 3 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-surveillance-report-3.pdf
     May 01, 2022 - • Other key adverse event outcomes (i.e., psychosis, cannabis use disorder, cognitive deficits) … ) Insufficient (1) Abbreviations: CBD = cannabidiol; CBDV = cannabidivarin; SAE = serious adverse event … ; SOE = strength of evidence; THC = tetrahydrocannabinol; WAE = withdrawal due to adverse event. … ; SOE = strength of evidence; THC = tetrahydrocannabinol; WAE = withdrawal due to adverse event … ; SOE = strength of evidence; THC = tetrahydrocannabinol; WAE = withdrawal due to adverse event

340. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 3 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-surveillance-report-3_0.pdf
     May 01, 2022 - • Other key adverse event outcomes (i.e., psychosis, cannabis use disorder, cognitive deficits) … ) Insufficient (1) Abbreviations: CBD = cannabidiol; CBDV = cannabidivarin; SAE = serious adverse event … ; SOE = strength of evidence; THC = tetrahydrocannabinol; WAE = withdrawal due to adverse event. … ; SOE = strength of evidence; THC = tetrahydrocannabinol; WAE = withdrawal due to adverse event … ; SOE = strength of evidence; THC = tetrahydrocannabinol; WAE = withdrawal due to adverse event